BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Radley A, Tait J, Dillon JF. DOT-C: A cluster randomised feasibility trial evaluating d irectly o bserved an t i-H C V therapy in a population receiving opioid substitute therapy from community pharmacy. International Journal of Drug Policy 2017;47:126-36. [DOI: 10.1016/j.drugpo.2017.05.042] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Marshall AD, Rance J, Grebely J, Treloar C. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Int J Drug Policy 2022;102:103610. [PMID: 35151085 DOI: 10.1016/j.drugpo.2022.103610] [Reference Citation Analysis]
2 Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy 2020;86:102964. [DOI: 10.1016/j.drugpo.2020.102964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lazarus JV, Picchio CA, Guy D, Aleman S, James C, Nava FA, Øvrehus A, Turnes J, Ward JW, Ustianowski A. Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. Clin Res Hepatol Gastroenterol 2021;45:101564. [PMID: 33740477 DOI: 10.1016/j.clinre.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Radley A, de Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, Fraser A, Dillon JF. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol 2020;5:809-18. [PMID: 32526210 DOI: 10.1016/S2468-1253(20)30120-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
5 Doyle JS, Scott N, Sacks-Davis R, Pedrana AE, Thompson AJ, Hellard ME; Eliminate Hepatitis C Partnership. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. Aliment Pharmacol Ther 2019;49:1223-9. [PMID: 30908706 DOI: 10.1111/apt.15210] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
6 Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, Treloar C. Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy 2017;47:26-33. [DOI: 10.1016/j.drugpo.2017.08.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
7 Radley A, de Bruin M, Inglis SK, Donnan PT, Dillon JF. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. BMJ Open 2018;8:e021443. [PMID: 30552244 DOI: 10.1136/bmjopen-2017-021443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
8 Enkelmann J, Gassowski M, Nielsen S, Wenz B, Roß S, Marcus U, Bremer V, Zimmermann R; DRUCK Study group. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. Harm Reduct J 2020;17:7. [PMID: 31924208 DOI: 10.1186/s12954-019-0338-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
9 Graupera I, Lammert F. Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden. Journal of Hepatology 2018;69:562-3. [DOI: 10.1016/j.jhep.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Donaldson SR, Radley A, Dillon JF. Identifying the Hidden Population: Former Intravenous Drug Users Who Are No Longer in Contact with Services. "Ask a Friend". Diagnostics (Basel) 2021;11:170. [PMID: 33504077 DOI: 10.3390/diagnostics11020170] [Reference Citation Analysis]
11 Abdelwadoud M, Mattingly TJ 2nd, Seguí HA, Gorman EF, Perfetto EM. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. Patient 2021;14:471-84. [PMID: 33372245 DOI: 10.1007/s40271-020-00489-6] [Reference Citation Analysis]
12 Levander XA, Vega TA, Seaman A, Korthuis PT, Englander H. Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. Int J Drug Policy 2021;:103356. [PMID: 34226111 DOI: 10.1016/j.drugpo.2021.103356] [Reference Citation Analysis]
13 Lazarus JV, Øvrehus A, Demant J, Krohn-Dehli L, Weis N. The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). BMJ Open 2020;10:e039724. [PMID: 33168560 DOI: 10.1136/bmjopen-2020-039724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
15 Hellard M, Scott N, Sacks-davis R, Pedrana A. Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. Journal of Hepatology 2018;68:383-5. [DOI: 10.1016/j.jhep.2017.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Bird K, Socías ME, Ti L. Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy. Int J Drug Policy 2018;59:1-2. [PMID: 29960218 DOI: 10.1016/j.drugpo.2018.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Mcdermott CL, Lockhart CM, Devine B. Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. Journal of Virus Eradication 2018;4:118-22. [DOI: 10.1016/s2055-6640(20)30255-7] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Palmateer NE, McAuley A, Dillon JF, McDonald S, Yeung A, Smith S, Barclay S, Hayes P, Shepherd SJ, Gunson RN, Goldberg DJ, Hickman M, Hutchinson SJ. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction 2021;116:2893-907. [PMID: 33651446 DOI: 10.1111/add.15459] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
19 Mason LMK, Veldhuijzen IK, Duffell E, van Ahee A, Bunge EM, Amato-Gauci AJ, Tavoschi L. Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review. J Viral Hepat 2019;26:1431-53. [PMID: 31332919 DOI: 10.1111/jvh.13182] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res 2019;19:765. [PMID: 31660966 DOI: 10.1186/s12913-019-4635-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
21 Roche R, Simmons R, Crawshaw AF, Fisher P, Pareek M, Morton W, Shryane T, Poole K, Verma A, Campos-Matos I, Mandal S. What do primary care staff know and do about blood borne virus testing and care for migrant patients? A national survey. BMC Public Health 2021;21:336. [PMID: 33573638 DOI: 10.1186/s12889-020-10068-x] [Reference Citation Analysis]
22 Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
23 Buchanan R, Cooper K, Grellier L, Khakoo SI, Parkes J. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective. J Viral Hepat 2020;27:36-44. [PMID: 31520434 DOI: 10.1111/jvh.13207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Swan D, Cullen W, Macias J, Oprea C, Story A, Surey J, Vickerman P, Lambert JS. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol. Expert Rev Gastroenterol Hepatol 2018;12:303-14. [PMID: 29300496 DOI: 10.1080/17474124.2018.1424541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
25 Avramovic G, Reilly M, Cullen W, Macías J, McCombe G, McHugh T, Oprea C, Story A, Surey J, Sabin C, Bivegete S, Vickerman P, Walker J, Ward Z, Lambert JS. HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities. Int J Infect Dis 2020;101:374-9. [PMID: 32992012 DOI: 10.1016/j.ijid.2020.09.1445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Byrne C, Radley A, Inglis SK, Beer LJZ, Palmer N, Pham MD, Healy B, Doyle JS, Donnan P, Dillon JF. Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV). BMJ Open 2020;10:e036501. [PMID: 32868356 DOI: 10.1136/bmjopen-2019-036501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Harris M, Rhodes T. Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. Int J Drug Policy 2018;60:24-32. [PMID: 30092546 DOI: 10.1016/j.drugpo.2018.07.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
28 Ledezma-morales M, Amariles P, Salazar-ospina A, Duque-zapata N, Gómez Cárdenas J, Vargas-peláez CM, Rossi FA. Effect of strategic purchasing of antiviral drugs and the clinical pathway for the treatment of Chronic Hepatitis C in Colombia (hepC-STRATEGY): study protocol for a quasi-experimental study. Journal of Pharmaceutical Health Services Research 2021;12:173-80. [DOI: 10.1093/jphsr/rmaa032] [Reference Citation Analysis]
29 Gunn J, Higgs P. Pharmacy-led hepatitis C treatment pathways to help ensure elimination. The Lancet Gastroenterology & Hepatology 2019;4:12-3. [DOI: 10.1016/s2468-1253(18)30380-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Patel EU, Solomon SS, Mcfall AM, Srikrishnan AK, Pradeep A, Nandagopal P, Laeyendecker O, Tobian AAR, Thomas DL, Sulkowski MS, Kumar MS, Mehta SH. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Int J Drug Policy 2018;57:51-60. [PMID: 29679811 DOI: 10.1016/j.drugpo.2018.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
31 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
32 Pedrana AE, Sacks-davis R, Doyle JS, Hellard ME. Pathways to the elimination of hepatitis C: prioritising access for all. Expert Review of Clinical Pharmacology 2017;10:1023-6. [DOI: 10.1080/17512433.2017.1383894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
33 Gunn J, Higgs P. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study. Res Social Adm Pharm 2020;16:1298-301. [PMID: 31003763 DOI: 10.1016/j.sapharm.2019.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Aleman S, Söderholm J, Büsch K, Kövamees J, Duberg AS. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver Int 2020;40:1832-40. [PMID: 32294288 DOI: 10.1111/liv.14469] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]